Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: Report from an International DLBCL Rituximab-CHOP Consortium Program Study

Blood

Volumn 120, Issue 19, 2012, Pages 3986-3996

  Xu Monette, Zijun Y ^a   Wu, Lin ^b   Visco, Carlo ^c   Tai, Yu Chuan ^b   Tzankov, Alexander ^d   Liu, Wei Min ^b   Montes Moreno, Santiago ^e   Dybkær, Karen ^f   Chiu, April ^g   Orazi, Attilio ^h   Zu, Youli ⁱ   Bhagat, Govind ^j   Richards, Kristy L ^k   Hsi, Eric D ^l   Zhao, X Frank ^m   Choi, William W L ⁿ   Zhao, Xiaoying ^o   Van Krieken, J Han ^p   Huang, Qin ^q   Huh, Jooryung ^r   Ai, Weiyun ^s   Ponzoni, Maurilio ^t   Ferreri, Andrés J M ^t   Zhou, Fan ^u   Kahl, Brad S ^v   Winter, Jane N ^w   Xu, Wei ^x   Li, Jianyong ^x   Go, Ronald S ^y   Li, Yong ^z   Piris, Miguel A ^e   Møller, Michael B ^aa   Miranda, Roberto N ^a   Abruzzo, Lynne V ^a   Medeiros, L Jeffrey ^a   Young, Ken H ^a   more..

^a UNIVERSITY OF TEXAS   (United States)

^b ROCHE MOLECULAR SYSTEMS   (United States)

^c SAN BORTOLO HOSPITAL   (Italy)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^f AARHUS UNIVERSITY HOSPITAL   (Denmark)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^h WEILL CORNELL MEDICAL COLLEGE   (United States)

ⁱ HOUSTON METHODIST HOSPITAL   (United States)

^j NewYork Presbyterian Hospital   (United States)

^k UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^l LERNER RESEARCH INSTITUTE   (United States)

^m UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

ⁿ UNIVERSITY OF HONG KONG   (Hong Kong)

^o ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^p RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^q CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^r University of Ulsan College of Medicine   (South Korea)

^s UNIVERSITY OF CALIFORNIA   (United States)

^t SAN RAFFAELE HOSPITAL   (Italy)

^u Southwest Washington Medical Center   (United States)

^v University of Wisconsin Health   (United States)

^w NORTHWESTERN UNIVERSITY   (United States)

^x NANJING MEDICAL UNIVERSITY   (China)

^y GUNDERSEN LUTHERAN MEDICAL CENTER   (United States)

^z UNIVERSITY OF LOUISVILLE   (United States)

^aa ODENSE UNIVERSITY HOSPITAL   (Denmark)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DNA BINDING PROTEIN; DOXORUBICIN; HELIX LOOP HELIX PROTEIN; PREDNISOLONE; PROTEIN P53; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE MARKER; FEMALE; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MOTIF; TREATMENT RESPONSE;

EID: 84868602463     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-05-433334     Document Type: Article

References (50)

1. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403(6769):503-511. (Pubitemid 30082188)
2. Pfreundschuh M, Kuhnt E, Trumper L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011;12(11):1013-1022.
3. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235-242. (Pubitemid 34438862)
4. Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 2010;116(12):2040-2045.
5. Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184-4190.
6. Levine AJ, Oren M. The first 30 years of p53: growing ever more complex. Nat Rev Cancer. 2009;9(10):749-758.
7. Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell. 2009;137(3): 413-431.
8. Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992;356(6366):215-221.
9. Gudkov AV, Komarova EA. The role of p53 in determining sensitivity to radiotherapy. Nat Rev Cancer. 2003;3(2):117-129. (Pubitemid 37328879)
10. Gaidarenko O, Xu Y. Transcription activity is required for p53-dependent tumor suppression. Oncogene. 2009;28(49):4397-4401.
11. Palacios G, Moll UM. Mitochondrially targeted wild-type p53 suppresses growth of mutant p53 lymphomas in vivo. Oncogene. 2006;25(45): 6133-6139. (Pubitemid 44562412)
12. Levine AJ, Vosburgh E. P53 mutations in lymphomas: position matters. Blood. 2008;112(8):2997- 2998.
13. Xu-Monette ZY, Medeiros LJ, Li Y, et al. Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies. Blood. 2012;119(16):3668- 3683.
14. Mihara M, Erster S, Zaika A, et al. p53 has a direct apoptogenic role at the mitochondria. Mol Cell. 2003;11(3):577-590. (Pubitemid 36385115)
15. Petitjean A, Mathe E, Kato S, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat. 2007;28(6):622-629. (Pubitemid 46744292)
16. Young KH, Weisenburger DD, Dave BJ, et al. Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAIL receptor-2, predict for poor survival in diffuse large B-cell lymphoma. Blood. 2007;110(13): 4396-4405. (Pubitemid 351377806)
17. Young KH, Leroy K, Moller MB, et al. Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. Blood. 2008; 112(8):3088-3098.
18. Joerger AC, Ang HC, Fersht AR. Structural basis for understanding oncogenic p53 mutations and designing rescue drugs. Proc Natl Acad Sci U SA. 2006;103(41):15056-15061. (Pubitemid 44583163)
19. Joerger AC, Fersht AR. Structural biology of the tumor suppressor p53. Annu Rev Biochem. 2008; 77:557-582.
20. Kato S, Han SY, Liu W, et al. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by highresolution missense mutation analysis. Proc Natl Acad Sci U S A. 2003;100(14):8424-8429. (Pubitemid 36842561)
21. Xu-Monette ZY, Young KH. The TP53 tumor suppressor and autophagy in malignant lymphoma. Autophagy. 2012;8(5):842-845.
22. Vousden KH, Prives C. P53 and prognosis: new insights and further complexity. Cell. 2005;120(1): 7-10. (Pubitemid 40094596)
23. Leroy K, Haioun C, Lepage E, et al. p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas. Ann Oncol. 2002;13(7):1108-1115.
24. Kerbauy FR, Colleoni GW, Saad ST, et al. Detection and possible prognostic relevance of p53 gene mutations in diffuse large B-cell lymphoma. An analysis of 51 cases and review of the literature. Leuk Lymphoma. 2004;45(10):2071-2078. (Pubitemid 39232856)
25. Liu YY, Yao SN, Zhao Y, et al. PTEN tumor suppressor plays less prognostic role than P53 tumor suppressor in diffuse large B-cell lymphoma. Leuk Lymphoma. 2010;51(9):1692-1698.
26. Weiner GJ. Rituximab: mechanism of action. Semin Hematol. 2010;47(2):115-123.
27. Walshe CA, Beers SA, French RR, et al. Induction of cytosolic calcium flux by CD20 is dependent upon B Cell antigen receptor signaling. J Biol Chem. 2008;283(25):16971-16984.
28. Daniels I, Turzanski J, Haynes AP. A requirement for calcium in the caspase-independent killing of Burkitt lymphoma cell lines by Rituximab. Br J Haematol. 2008;142(3):394-403. (Pubitemid 351962172)
29. Unruh TL, Zuccolo J, Beers SA, Kanevets U, Shi Y, Deans JP. Therapeutic (high) doses of rituximab activate calcium mobilization and inhibit B-cell growth via an unusual mechanism triggered independently of both CD20 and Fcgamma receptors. J Immunother. 2010;33(1):30-39.
30. Kheirallah S, Caron P, Gross E, et al. Rituximab inhibits B-cell receptor signaling. Blood. 2010; 115(5):985-994.
31. Murray-Zmijewski F, Slee EA, Lu X. A complex barcode underlies the heterogeneous response of p53 to stress. Nat Rev Mol Cell Biol. 2008;9(9): 702-712.
32. Jaffe ES. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology Am Soc Hematol Educ Program. 2009;2009:523-531.
33. Visco C, Li Y, Xu-Monette ZY, et al. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: A report from the International DLBCL Rituximab- CHOP consortium program study. Leukemia. 2012;26(9):2103-2113.
34. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17(4):1244.
35. Cheson BD. The International Harmonization Project for response criteria in lymphoma clinical trials. Hematol Oncol Clin North Am. 2007;21(5): 841-854. (Pubitemid 47484137)
36. Grollman AP, Shibutani S, Moriya M, et al. Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc Natl Acad Sci U S A. 2007; 104(29):12129-12134. (Pubitemid 47185641)
37. Rivlin N, Brosh R, Oren M, Rotter V. Mutations in the p53 tumor suppressor gene: important milestones at the various steps of tumorigenesis. Genes Cancer. 2011;2(4):466-474.
38. Du M, Peng H, Singh N, Isaacson PG, Pan L. The accumulation of p53 abnormalities is associated with progression of mucosa-associated lymphoid tissue lymphoma. Blood. 1995;86(12):4587-4593.
39. Ikezoe T, Yang J, Nishioka C, Yokoyama A. p53 is critical for the Aurora B kinase inhibitor-mediated apoptosis in acute myelogenous leukemia cells. Int J Hematol. 2010;91(1):69-77.
40. Wang F, Liu J, Robbins D, et al. Mutant p53 exhibits trivial effects on mitochondrial functions which can be reactivated by ellipticine in lymphoma cells. Apoptosis. 2011;16(3):301-310.
41. Cinti C, Claudio PP, Luca AD, et al. A serine 37 mutation associated with two missense mutations at highly conserved regions of p53 affect pro-apoptotic genes expression in a T-lymphoblastoid drug resistant cell line. Oncogene. 2000;19(44):5098-5105.
42. Ahn BY, Trinh DL, Zajchowski LD, Lee B, Elwi AN, Kim SW. Tid1 is a new regulator of p53 mitochondrial translocation and apoptosis in cancer. Oncogene. 2010;29(8):1155-1166.
43. Lenz G, Staudt LM. Aggressive lymphomas. N Engl J Med. 2010;362(15):1417-1429.
44. Chan WJ. Pathogenesis of diffuse large B cell lymphoma. Int J Hematol. 2010;92(2):219-230.
45. Fu K, Weisenburger DD, Choi WW, et al. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol. 2008;26(28):4587-4594.
46. Suzuki H, Kurita M, Mizumoto K, et al. The ARF tumor suppressor inhibits BCL6-mediated transcriptional repression. Biochem Biophys Res Commun. 2005;326(1):242-248.
47. Zeng Y, Kotake Y, Pei XH, Smith MD, Xiong Y. p53 binds to and is required for the repression of Arf tumor suppressor by HDAC and polycomb. Cancer Res. 2011;71(7):2781-2792.
48. Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev. 1999;13(20):2658- 2669.
49. Gonzalez D, Martinez P, Wade R, et al. Mutational Status of the TP53 Gene As a Predictor of Response and Survival in Patients With Chronic Lymphocytic Leukemia: Results From the LRF CLL4 Trial. J Clin Oncol. 2011;29(16):2223-2229.
50. Rücker FG, Schlenk RF, Bullinger L, et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood. 2012;119(9):2114-2121.